UICMES | Pre-Test UICMES | Pre-Test Name * Name First First Last Last Email * Select Event Attended: * Session 1, June 12, 2024: Lung, Head, Neck, and Colorectal Cancers Session 2, June 19, 2024: GU and Breast Cancers A 70 year male see he’s PCP for a persistent 2 month cough and 15 lbs. weight loss. CT imaging demonstrates a 5 cm right upper lobe mass. He subsequently completes a PET scan which demonstrates FDG avidity in right upper lobe mass as well as a right hilar lymph node. Pathology right upper lobe mass and station 10 right hilar lymph node biopsies from an Endobronchial ultrasound bronchoscopy confirm the diagnosis of small cell lung cancer. MRI imaging of the brain is negative for intracranial metastases. 1. What treatment would you offer? * A. Platinum based chemotherapy with concurrent radiation B. Platinum based chemotherapy with concurrent radiation followed by durvalumab consolidation C. Platinum based chemotherapy alone D. Platinum based chemotherapy with durvalumab followed by durvalumab maintenance 2. Which of the following molecular alterations do NOT have an FDA approval for targeted therapy as monotherapy in the first-line setting? * A. EGFR ex19 deletion B. KRAS G12C mutation C. ALK rearrangement positive D. METex14 skipping mutation 3. You have a 50 year old male with HPV negative HNSCC of the oropharynx who is concerned about side effects since he works as a sommelier. Tumor board recommends resection. After surgery he has a positive margin. In addition to chemotherapy which of the following might one consider to reduce short-term and long-term side effects? * A. Referral for FMISO center for tumor hypoxia assessment and de-escalation to 30Gy IMRT B. Referral for Intensity Modulated Proton Therapy C. Stereotactic Radiotherapy D. Conventional IMRT but omitting chemotherapy 1. 76yo M with 11cm clear cell RCC + sarcomatoid features +LN, s/p nephrectomy, recommended tx? * A. Observation B. Ipi/nivo C. Pembro x1 year D. Pembro x 2 years 2. 68 y.o M with mCSPC received ADT + Abiraterone/Prednisone + Docetaxel found to have a rising PSA on routine follow up. PSMA-PET ordered and revealed: new osseous and liver metastatic lesions. He is having new bony pain. NGS is sent and the patient is without actionable alterations What treatment would you offer next? * A. Enzalutamide B. Cabazitaxel C. 177Lu-PSMA-617 D. Ra-223 (Xofigo) E. Sipuleucel-T 3. DESTINY-Breast06 compared TDX-d to 1L chemotherapy in patients with endocrine refractory HR+/HER2 low or ultralow mBC who have had prior endocrine therapy, CDK 4/6 inhibitor, or targeted therapies and experienced disease progression. Which of the following statements best describes the outcome of the trial? * A. Statically significant PFS benefit with TDXd; mPFS of T-DXd 13.2 mo vs TPC 8.1 mo B. Statistically significant OS benefit with TDXd; OS of TDXd 87.6% vs TPC 81.7% C. Statistically significant PFS and OS benefit with TDXd D. Statistically significant PFS benefit with TDXd only in HER2-low population, but no PFS benefit in HER2 ultra-low Submit If you are human, leave this field blank. Δ
